These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 1976795)

  • 21. Assessing surrogates as trial endpoints using mixed models.
    Korn EL; Albert PS; McShane LM
    Stat Med; 2005 Jan; 24(2):163-82. PubMed ID: 15515150
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CD4 masking during human immunodeficiency virus type 1 infection, quantified on peripheral blood lymphocytes, is a potential marker of disease progression.
    Carrière D; Vendrell J; Berthier A; Atoui N; Salhi SL; Reynes J; Gros P; Fontaine C; Jansen A; Huguet M; Ait-Cheik L; Pau B
    J Infect Dis; 1996 Mar; 173(3):565-73. PubMed ID: 8627018
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Current status of HIV therapy: I. Antiretroviral agents.
    Hoth DF; Myers MW; Stein DS
    Hosp Pract (Off Ed); 1992 Sep; 27(9):145-56. PubMed ID: 1381716
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quantification of HIV-1 virus load under zidovudine therapy in patients with symptomatic HIV infection: relation to disease progression.
    Molina JM; Ferchal F; Chevret S; Barateau V; Poirot C; Morinet F; Modai J
    AIDS; 1994 Jan; 8(1):27-33. PubMed ID: 7912084
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Systemic DPP4 activity is reduced during primary HIV-1 infection and is associated with intestinal RORC
    Ploquin MJ; Casrouge A; Madec Y; Noël N; Jacquelin B; Huot N; Duffy D; Jochems SP; Micci L; Lécuroux C; Boufassa F; Booiman T; Garcia-Tellez T; Ghislain M; Grand RL; Lambotte O; Kootstra N; Meyer L; Goujard C; Paiardini M; Albert ML; Müller-Trutwin M
    J Int AIDS Soc; 2018 Jul; 21(7):e25144. PubMed ID: 29987877
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of intravenous immunoglobulin (IVIG) on CD4+ lymphocyte decline in HIV-infected children in a clinical trial of IVIG infection prophylaxis. The National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group.
    Mofenson LM; Bethel J; Moye J; Flyer P; Nugent R
    J Acquir Immune Defic Syndr (1988); 1993 Oct; 6(10):1103-13. PubMed ID: 8105072
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Considerations in the evaluation of surrogate endpoints in clinical trials. summary of a National Institutes of Health workshop.
    De Gruttola VG; Clax P; DeMets DL; Downing GJ; Ellenberg SS; Friedman L; Gail MH; Prentice R; Wittes J; Zeger SL
    Control Clin Trials; 2001 Oct; 22(5):485-502. PubMed ID: 11578783
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Concorde Coordinating Committee.
    Lancet; 1994 Apr; 343(8902):871-81. PubMed ID: 7908356
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Methodological issues in the use of composite endpoints in clinical trials: examples from the HIV field.
    Wittkop L; Smith C; Fox Z; Sabin C; Richert L; Aboulker JP; Phillips A; Chêne G; Babiker A; Thiébaut R;
    Clin Trials; 2010 Feb; 7(1):19-35. PubMed ID: 20156955
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Human immunodeficiency virus type 1 RNA level and CD4 count as prognostic markers and surrogate end points: a meta-analysis. HIV Surrogate Marker Collaborative Group.
    AIDS Res Hum Retroviruses; 2000 Aug; 16(12):1123-33. PubMed ID: 10954887
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Optimal monitoring strategies for guiding when to switch first-line antiretroviral therapy regimens for treatment failure in adults and adolescents living with HIV in low-resource settings.
    Chang LW; Harris J; Humphreys E
    Cochrane Database Syst Rev; 2010 Apr; (4):CD008494. PubMed ID: 20393969
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Future treatment strategies in HIV infection.
    Dormont J
    AIDS; 1994 Sep; 8 Suppl 3():S31-3. PubMed ID: 7840915
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Estimated biological markers of progression in human immunodeficiency virus infection].
    Bélec L; Ripoll L; Matta F; Mbopi Kéou FX; Cotigny S; Longuet MF; Jacob A
    Ann Biol Clin (Paris); 1992; 50(9):621-37. PubMed ID: 1298168
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of predictive markers of HIV disease progression in vaccine trials.
    Gurunathan S; Habib RE; Baglyos L; Meric C; Plotkin S; Dodet B; Corey L; Tartaglia J
    Vaccine; 2009 Mar; 27(14):1997-2015. PubMed ID: 19200450
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Changes in surrogate laboratory markers, clinical endpoints, and health-related quality of life in patients infected with the human immunodeficiency virus.
    Chan KS; Revicki DA
    Eval Health Prof; 1998 Jun; 21(2):265-81. PubMed ID: 10183347
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictive value for survival of soluble tumor necrosis factor receptors p55 and p75 during zidovudine-containing treatment in symptomatic human immunodeficiency virus type 1 infection.
    Frissen PH; Weverling GJ; Endert E; Jansen J; Sauerwein HP; Lange JM
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Aug; 12(5):482-8. PubMed ID: 8757425
    [TBL] [Abstract][Full Text] [Related]  

  • 37. AIDS: Part II.
    Kessler HA; Bick JA; Pottage JC; Benson CA
    Dis Mon; 1992 Oct; 38(10):691-764. PubMed ID: 1396036
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A comparison of two dosing regimens of zidovudine in Thai adults with early symptomatic HIV infection. Conducting clinical HIV trials in South-East Asia.
    Phanuphak P; Grayson ML; Sirivichayakul S; Suwanagool S; Ruxrungtham K; Hanvanich M; Ratanasuwan W; Ubolyam S; Hughes MD; Wanke CA; Hammer SM
    Aust N Z J Med; 2000 Feb; 30(1):11-20. PubMed ID: 10800872
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Importance of surrogate markers in evaluation of antiviral therapy for HIV infection.
    Deyton L
    JAMA; 1996 Jul; 276(2):159-60. PubMed ID: 8656509
    [No Abstract]   [Full Text] [Related]  

  • 40. Meta-analysis for the evaluation of potential surrogate markers.
    Daniels MJ; Hughes MD
    Stat Med; 1997 Sep; 16(17):1965-82. PubMed ID: 9304767
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.